4.8 Article

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation

期刊

NATURE COMMUNICATIONS
卷 10, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-08115-8

关键词

-

资金

  1. Canadian Institutes of Health Research [FDN-1542284, MOP-119356]
  2. Canadian Cancer Society Research Institute [703209]
  3. Princess Margaret Foundation
  4. NIH [RO1 CA207288]
  5. Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers from Japan Society for the Promotion of Science and A Long-Term Overseas Research Fellowship from Sumitomo Life Welfare and Culture Foundation
  6. Cancer Research Society
  7. George and Helen Vari Foundation
  8. Canada Foundation for Innovation

向作者/读者索取更多资源

Deregulation of the RAS GTPase cycle due to mutations in the three RAS genes is commonly associated with cancer development. Protein tyrosine phosphatase SHP2 promotes RAF-to-MAPK signaling pathway and is an essential factor in RAS-driven oncogenesis. Despite the emergence of SHP2 inhibitors for the treatment of cancers harbouring mutant KRAS, the mechanism underlying SHP2 activation of KRAS signaling remains unclear. Here we report tyrosyl-phosphorylation of endogenous RAS and demonstrate that KRAS phosphorylation via Src on Tyr32 and Tyr64 alters the conformation of switch I and II regions, which stalls multiple steps of the GTPase cycle and impairs binding to effectors. In contrast, SHP2 dephosphorylates KRAS, a process that is required to maintain dynamic canonical KRAS GTPase cycle. Notably, Src- and SHP2-mediated regulation of KRAS activity extends to oncogenic KRAS and the inhibition of SHP2 disrupts the phosphorylation cycle, shifting the equilibrium of the GTPase cycle towards the stalled 'dark state'.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据